Simultaneous oral therapeutic and intravenous 14 C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations

(2012) Xiaohui (Sophia) Xu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study

(2011) Sreeneeranj Kasichayanula et al.   CLINICAL THERAPEUTICS

The debate is over: accelerator MS provides the route to better drug-development paradigms/protocols

(2011) Dennis A Smith   Bioanalysis

Quantifying exploratory low dose compounds in humans with AMS

(2010) Stephen R. Dueker et al.   ADVANCED DRUG DELIVERY REVIEWS

Pharmacokinetics of fexofenadine: Evaluation of a microdose and assessment of absolute oral bioavailability

(2010) Graham Lappin et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

(2009) M. Obermeier et al.   DRUG METABOLISM AND DISPOSITION

The utility of microdosing over the past 5 years

(2008) Graham Lappin et al.   Expert Opinion on Drug Metabolism & Toxicology